OVERVIEW
- Nearly half of patients in the APHINITY trial were overweight/obese.
- Overweight/obesity was associated with poorer survival outcomes.
- Higher chemotherapy discontinuation rates were found in patients with overweight/obesity.
- Obesity remained linked to poorer outcomes after adjusting for chemotherapy discontinuation rates.
STUDY DETAILS
APHINITY was a randomised, double-blind, phase III study comparing the addition of pertuzumab or placebo to adjuvant trastuzumab and chemotherapy in patients with HER2-positive early breast cancer.
The APHINITY trial was supported by F. Hoffmann-La Roche Ltd/Genentech and was designed by the Breast International Group (BIG) in collaboration with the sponsor.
The database was maintained at the Institut Jules Bordet Clinical Trials Support Unit (Brussels, Belgium), and the statistical analyses were carried out by Frontier Science Scotland.
TITLE OF PUBLICATION
Body mass index and weight changes in patients with HER2-positive early
breast cancer: A sub-analysis of the APHINITY trial
AUTHORS
Chiara Dauccia, Maria Alice Franzoi, Samuel Martel, Dominique Agbor-Tarh,
Shona Fielding, Martine Piccart, Jose Bines, Sibylle Loibl, Serena Di Cosimo,
Ines Vaz-Luis, Antonio Di Meglio, Lucia Del Mastro, Andrea Gombos,
Christine Desmedt, Guy Jerusalem, Linda Reaby, Tadeus Pienkowski,
Matteo Lambertini, Elisa Agostinetto, Evandro de Azambuja.
Publication Reference
European Journal of Cancer (EJC) | Volume 223| 115489 | Publication Year 2025
